| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of
*
Internal Medicine and
Pathology and Immunology, Washington University School of Medicine, St. Louis, MO
Both the type I (IFN-
) and type II (IFN-
) IFNs have been heavily implicated in the pathogenesis of systemic lupus erythematosus. To test the relative roles of these systems, congenic lupus-prone MRL/CD95lpr/lpr (MRL/lpr) mice lacking the type I IFN receptor (IFN-RI), type II IFN receptor (IFN-RII), or both, were derived. As expected, deficiency for IFN-RII protected MRL/lpr mice from the development of significant autoimmune-associated lymphadenopathy, autoantibodies, and renal disease. However, deficiency for the IFN-RI surprisingly worsened lymphoproliferation, autoantibody production, and end organ disease; animals doubly deficient for IFN-RI and IFN-RII developed an autoimmune phenotype intermediate between wild-type and IFN-RII-deficient animals, all correlating with an ability of type I IFN to suppress MRL B cell activation. Thus, type I IFNs protect against both the humoral and end organ autoimmune syndrome of MRL/lpr mice, independent of IFN-. These findings warrant caution in the use of type I IFN antagonists in the treatment of autoimmune diseases and suggest further investigation into the interplay between the types I and II IFNs during the ontogeny of pathogenic autoantibodies.
This article has been cited by other articles:
|
|
 |
|
  A.-M. Fairhurst, C. Xie, Y. Fu, A. Wang, C. Boudreaux, X. J. Zhou, R. Cibotti, A. Coyle, J. E. Connolly, E. K. Wakeland, et al. Type I Interferons Produced by Resident Renal Cells May Promote End-Organ Disease in Autoantibody-Mediated Glomerulonephritis J. Immunol., November 15, 2009; 183(10): 6831 - 6838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Agrawal, N. Jacob, E. Carreras, S. Bajana, C. Putterman, S. Turner, B. Neas, A. Mathian, M. N. Koss, W. Stohl, et al. Deficiency of Type I IFN Receptor in Lupus-Prone New Zealand Mixed 2328 Mice Decreases Dendritic Cell Numbers and Activation and Protects from Disease J. Immunol., November 1, 2009; 183(9): 6021 - 6029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Green, A. Laws, K. Kiefer, L. Busconi, Y.-M. Kim, M. M. Brinkmann, E. H. Trail, K. Yasuda, S. R. Christensen, M. J. Shlomchik, et al. Murine B Cell Response to TLR7 Ligands Depends on an IFN-{beta} Feedback Loop J. Immunol., August 1, 2009; 183(3): 1569 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Y. Lee, Y. Kumagai, Y. Li, O. Takeuchi, H. Yoshida, J. Weinstein, E. S. Kellner, D. Nacionales, T. Barker, K. Kelly-Scumpia, et al. TLR7-dependent and Fc{gamma}R-independent production of type I interferon in experimental mouse lupus J. Exp. Med., December 22, 2008; 205(13): 2995 - 3006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kobayashi, K. Takahashi, Y. Nagai, T. Shibata, M. Otani, S. Izui, S. Akira, Y. Gotoh, H. Kiyono, and K. Miyake Tonic B cell activation by Radioprotective105/MD-1 promotes disease progression in MRL/lpr mice Int. Immunol., July 1, 2008; 20(7): 881 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Atkinson, F. Qiao, H. Song, G. S. Gilkeson, and S. Tomlinson Low-Dose Targeted Complement Inhibition Protects against Renal Disease and Other Manifestations of Autoimmune Disease in MRL/lpr Mice J. Immunol., January 15, 2008; 180(2): 1231 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Asokan, J. Hua, K. A. Young, H. J. Gould, J. P. Hannan, D. M. Kraus, G. Szakonyi, G. J. Grundy, X. S. Chen, M. K. Crow, et al. Characterization of Human Complement Receptor Type 2 (CR2/CD21) as a Receptor for IFN-{alpha}: A Potential Role in Systemic Lupus Erythematosus J. Immunol., July 1, 2006; 177(1): 383 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Savarese, O.-w. Chae, S. Trowitzsch, G. Weber, B. Kastner, S. Akira, H. Wagner, R. M. Schmid, S. Bauer, and A. Krug U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7 Blood, April 15, 2006; 107(8): 3229 - 3234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Srivatsan and S. L. Peng Cutting Edge: Foxj1 Protects against Autoimmunity and Inhibits Thymocyte Egress J. Immunol., December 15, 2005; 175(12): 7805 - 7809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Kitching More Targeted Treatments for Lupus Nephritis: Is the Future (Nearly) Here? J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3146 - 3148. [Full Text] [PDF]
|
|
|
|
|
|
A. Schwarting, K. Paul, S. Tschirner, J. Menke, T. Hansen, W. Brenner, V. R. Kelley, M. Relle, and P. R. Galle Interferon-{beta}: A Therapeutic for Autoimmune Lupus in MRL-Faslpr Mice J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3264 - 3272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Christensen, M. Kashgarian, L. Alexopoulou, R. A. Flavell, S. Akira, and M. J. Shlomchik Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus J. Exp. Med., July 18, 2005; 202(2): 321 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Subramanian, Y.-S. Yim, K. Liu, K. Tus, X. J. Zhou, and E. K. Wakeland Epistatic Suppression of Systemic Lupus Erythematosus: Fine Mapping of Sles1 to Less Than 1 Mb J. Immunol., July 15, 2005; 175(2): 1062 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mathian, A. Weinberg, M. Gallegos, J. Banchereau, and S. Koutouzov IFN-{alpha} Induces Early Lethal Lupus in Preautoimmune (New Zealand Black x New Zealand White)F1 but Not in BALB/c Mice J. Immunol., March 1, 2005; 174(5): 2499 - 2506. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
